AZMATICS: AZithroMycin/Asthma Trial In Community Settings
Information source: University of Wisconsin, Madison
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Azithromycin (Drug); Placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: University of Wisconsin, Madison Official(s) and/or principal investigator(s): David L Hahn, MD, MS, Principal Investigator, Affiliation: Wisconsin Research and Education Network (WREN)
Summary
The purpose of this study is to assess the effectiveness of the azalide macrolide
azithromycin in adults with persistent asthma.
Research Question: Will a 12-week treatment with the antibiotic, azithromycin, result in a
statistically significant and clinically meaningful improvement in overall asthma symptoms
and other patient-oriented asthma outcomes one year after initiation of treatment of adult
primary care patients with asthma?
Experimental Design: The investigators propose a one-year randomized, placebo-controlled,
blinded (investigator, patient, data collector, data analyst) trial of 12 weekly doses of
azithromycin/placebo as adjunctive therapy (in addition to usual care) in 100 adult asthma
patients recruited from practice-based research networks (e. g., Wisconsin Research and
Education Network (WREN) and others). This "practical clinical trial" will (1) enroll a
representative sample of asthma patients encountered in the practices of primary care
physicians, (2) employ standard clinical trial methodology to ensure internally valid
results and (3) measure outcomes important to patients, so that the results will be valid
and applicable to the kinds of asthma patients encountered by family physicians and other
primary care providers.
Active study sites - Wisconsin: Augusta, Cross Plains, La Crosse, Marshfield, Milwaukee,
Madison, Mauston, Rice Lake, Tomah, Wausau; Colorado: Monument; Illinois: Peoria; Nevada:
Reno; North Carolina: Granite Falls; North Dakota: Minot; Ohio: Cleveland, Berea; Oklahoma:
Ardmore, Claremore, Edmond, Lawton, Oklahoma City, Stroud, Tulsa, Weatherford; Rhode Island:
East Providence
Clinical Details
Official title: AZMATICS: Azithromycin Asthma Trial In Community Settings
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Overall asthma symptoms, as measured by a 5-point scale
Secondary outcome: Asthma controlAsthma-specific quality-of-life Asthma exacerbations
Detailed description:
1. 0 PROTOCOL SYNOPSIS
Approximately 100 eligible adult patients with physician-diagnosed asthma will be randomized
to 12-week treatment with azithromycin, a widely marketed azalide antibiotic with an
excellent safety profile, or identical placebo as adjunctive therapy for usual care for
asthma. The following patient-reported data will be collected via Zoomerang™ (a
commercially-available data collection tool) periodically until one year after
randomization: (1) study medication adherence and side effects weekly until 12 weeks, (2)
asthma control and exacerbations every 6 weeks until 12 months, and (3) asthma quality of
life and asthma controller medication changes every 3 months until 12 months. The primary
hypothesis is that azithromycin will significantly improve asthma control (decrease symptoms
and medication use) by 3 months (end treatment) and the improvement will continue to 12
months (end study). The primary outcome variable is overall asthma symptoms. Secondary
outcomes are asthma medication use, quality of life and exacerbations. We will examine the
predictive value of baseline patient characteristics including age, sex, smoking, co-morbid
respiratory diagnoses and degree of airflow limitation. We will also examine for any
imbalances between study groups in controller medication use, other antibiotic prescriptions
and acute respiratory illnesses during the one-year study period.
We will enroll subjects from the practices of Wisconsin Research and Education Network
(WREN) members, UW Department of Family Medicine physicians, Dean Medical Center primary
care physicians, and from other practice-based research networks (PBRNs), medical group
practices and individual primary care practices throughout North America.
Patients with physician-diagnosed asthma aged 18 and older will be identified at
point-of-service (office, urgent care, emergency room or hospital), by administrative data
base review, or by physician recall. Most subjects will be the patients of study
physicians. Other physicians in the group practice may refer subjects. Subjects also may
be self-referred after responding to posters placed in the clinics. Some sites may elect to
identify cases by medical record or database review, in which case only the personal
physician may initiate patient contacts.
Treatment is azithromycin tablets, 600 milligrams orally once daily for 3 days, then 600
milligrams once weekly for an additional 11 weeks (total dose 8400 milligrams) or identical
placebo, in addition to usual care for asthma.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 18 and older (and at least 50 kg/110 pounds)
- The lower weight limit was chosen to avoid exposure to greater than 12 mg/kg/day
of azithromycin (a currently recommended dose for children)
- We specify no upper age limit because asthma occurs throughout the age range and
because asthma in the elderly is particularly severe and warrants inclusion.
- Physician-diagnosed asthma
- At the time of randomization, eligible subjects must either:
- be having a documented asthma exacerbation OR
- be reporting at least mild persistent asthma symptoms, as defined by GINA
(Global Initiative for Asthma)
- Subjects must also have asthma symptoms for at least six months prior to
randomization
- Documentation of objective evidence of reversible airway obstruction, either
spontaneously or after treatment, is required prior to randomization. This
requirement can be met by documentary evidence, within 2 years of randomization, of
either:
- a 12% or greater (and ≥200 mL) change in FEV1 OR
- a 25% or greater (and >60 L/min) change in PEFR either spontaneously or as a
result of treatment
Exclusion Criteria:
- Not English literate or without email and internet access
- Macrolide allergy
- Pregnancy or lactation
- Females of childbearing potential must agree to use an acceptable form of
contraception during the treatment period
- Chronic use of macrolides, tetracyclines or quinolones Chronic use is defined as 4 or
more weeks of continuous use within 6 months of randomization
- Asthma symptoms for less than 6 months prior to randomization Asthma symptoms must be
present for at least 6 months to exclude patients without true chronic asthma
- Unstable asthma requiring immediate emergency care All patients with asthma
exacerbations will receive usual urgent or emergency care for asthma and must be
improving or stable in the judgment of the treating physician prior to being enrolled
- Specified co-morbidities likely to interfere with study assessments or follow up.
Excluded comorbidities include:
- cystic fibrosis
- obstructive sleep apnea requiring CPAP
- cardiomyopathy
- congestive heart failure
- terminal cancer
- alcohol or other drug abuse
- or any other serious medical condition that, in the opinion of the study
physician, would seriously interfere with or preclude assessment of study
outcomes or completion of study assessments
- Specified medical conditions for which macrolide administration may possibly be
hazardous
- Patients with acute or chronic hepatitis, cirrhosis or other liver disease, chronic
kidney disease, or history of prolonged cardiac repolarization and QT interval or
torsades de pointes, are excluded
- Specified medications for which close monitoring has been recommended in the setting
of macrolide administration Patients taking digoxin, theophylline, warfarin,
ergotamine or dihydroergotamine, triazolam, carbamazepine, cyclosporine, hexobarbital
or phenytoin are excluded.
- If any of these medications are started after randomization and before
completion of the 12-week treatment phase, study medication will be discontinued
and the patient may remain in the study.
The intent of this protocol is to enroll a broadly generalizable sample of adult patients
with physician-diagnosed asthma, either stable persistent or in exacerbation.
Locations and Contacts
ANSR, Peoria, Illinois 61602, United States
AAFP National Research Network, Kansas City, Kansas 66211, United States
RAP - Cleveland Clinic, Cleveland, Ohio 44130, United States
University of Oklahoma Health Sciences Center (OUHSC) and Oklahoma Physicians Resource/Research Network (OKPRN), Oklahoma City, Oklahoma 73104, United States
Wisconsin Research and Education Network (WREN), Madison, Wisconsin 53713, United States
Additional Information
Patient perspective/literature review Infectious asthma research/annotated bibliography Book that reviews the topic of infection as a treatable cause for asthma
Related publications: Hahn DL, Plane MB. Feasibility of a practical clinical trial for asthma conducted in primary care. J Am Board Fam Pract. 2004 May-Jun;17(3):190-5. Hahn DL. Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract. 1995 Oct;41(4):345-51. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? Ann Allergy Asthma Immunol. 1999 Oct;83(4):271-88, 291; quiz 291-2. Review. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials. 2006 Jun;1(2):e11. Epub 2006 Jun 30.
Starting date: January 2006
Last updated: December 11, 2013
|